Versant Ventures III, LLC - 18 Aug 2023 Form 3 Insider Report for Skye Bioscience, Inc. (SKYE)

Role
10%+ Owner
Signature
Versant Ventures III, LLC, By /s/ Max Eisenberg, Chief Operating Officer
Issuer symbol
SKYE
Transactions as of
18 Aug 2023
Net transactions value
$0
Form type
3
Filing time
28 Aug 2023, 16:16:33 UTC

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SKYE Common Stock 498,978,878 18 Aug 2023 By Versant Venture Capital III, L.P. F1
holding SKYE Common Stock 2,946,924 18 Aug 2023 By Versant Side Fund III, L.P. F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SKYE Warrant (Right to Buy) 18 Aug 2023 Common Stock 130,043,230 $0.0206 By Versant Venture Capital III, L.P. F1
holding SKYE Warrant (Right to Buy) 18 Aug 2023 Common Stock 768,124 $0.0206 By Versant Side Fund III, L.P. F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Securities are directly held by Versant Venture Capital III, L.P. ("Versant III"). Versant Ventures III, LLC ("Versant Ventures III") is the sole general partner of Versant III and may be deemed to share voting and dispositive power over the securities held by Versant III. Versant Ventures III disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein.
F2 Securities are directly held by Versant Side Fund III, L.P. ("Side Fund III"). Versant Ventures III is the sole general partner of Side Fund III and may be deemed to share voting and dispositive power over the securities held by Side Fund III. Versant Ventures III disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein.